The availability of antimicrobial agents for self-medication may increase and could include antibacterial agents for oral or topical use.
Wholesale deregulation of antibacterials would be undesirable and likely to encourage misuse of classes of agents currently important in the management of serious infections.
Changed regulation from Prescription-Only Medicine (POM) to Pharmacy (P) medicine of selected agents with indications for short-term use in specific minor infections and illness is likely to have advantages to the user.
However, safeguards to their use would need to be included in the Patient Information Leaflet (PIL).
Agents and indications for self-medication are discussed.
Any alteration in licensed status from POM to P will require careful risk-benefit assessment, including the likely impact on bacterial resistance.
Safety issues also include concerns relating to age of the user, pregnancy, underlying disease and the potential for drug interactions.
The importance of appropriate information with the PIL is emphasized, as is the role of the pharmacist, while ways of improving adverse event notification and monitoring are discussed.
The paucity of good denominator-controlled data on the prevalence of in-vitro resistance is highlighted, and recommendations for improving the situation are made. (...)
Mots-clés Pascal : Antibactérien, Résistance, Sensibilité résistance, Automédication, Résistance microorganisme, Association médicamenteuse, Voie orale, Interaction médicamenteuse, Test sensibilité médicamenteuse, Voie locale, Voie externe, In vitro, Infection, Chimiothérapie, In vivo, Traitement, Efficacité traitement, Article synthèse, Homme, Court terme, Information biomédicale, Facteur risque, Analyse risque, Analyse coût efficacité, Changement médicament
Mots-clés Pascal anglais : Antibacterial agent, Resistance, Sensitivity resistance, Self prescription, Microorganism resistance, Drug combination, Oral administration, Drug interaction, Drug susceptibility test, Local administration, Topical administration, In vitro, Infection, Chemotherapy, In vivo, Treatment, Treatment efficiency, Review, Human, Short term, Biomedical information, Risk factor, Risk analysis, Cost efficiency analysis, Drug switching
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0465047
Code Inist : 002B02S02. Création : 22/03/2000.